Current pharmacologic treatment of brain metastasis in non-small cell lung cancer.
Takae OkunoTakeshi IsobeYukari TsubataPublished in: Clinical & experimental metastasis (2024)
Lung cancer is a type of cancer that can metastasize to the lungs, brain, bones, liver, adrenal glands, and other organs; however, the occurrence of brain metastases is the most common event. Symptoms of brain metastasis include motor dysfunction, mental dysfunction, seizures, headaches, nausea, and vomiting, and significantly reduce the quality of life of cancer patients. Brain metastases are a poor prognostic factor, and controlling them is extremely important for prolonging prognosis and improving the quality of life. Currently, local surgery and radiotherapy are recommended for their treatment. However, recently, cancer treatments using molecular-targeted drugs and immune checkpoint inhibitors have been introduced, which may also be effective against brain metastases. Therefore, it is necessary to determine whether local or systemic therapy is optimal for each case. In this review, we focus on recent findings regarding drug therapy in treating brain metastases from advanced non-small cell lung cancer.
Keyphrases
- brain metastases
- small cell lung cancer
- advanced non small cell lung cancer
- papillary thyroid
- resting state
- white matter
- prognostic factors
- oxidative stress
- squamous cell
- early stage
- functional connectivity
- minimally invasive
- risk assessment
- stem cells
- depressive symptoms
- locally advanced
- lymph node metastasis
- sleep quality
- percutaneous coronary intervention